Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5906811 | 1.00 | ALDH1A1 (0.68) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL9741569 | 0.90 | MAOB (0.62) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL9738355 | 0.86 | MAOB (0.57) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL6504735 | 0.84 | MAPT (0.65) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL6504737 | 0.84 | MAPT (0.65) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL7028240 | 0.82 | MAOB (0.68) | ALDH1A1NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL12722758 | 0.82 | MAOB (0.53) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL31276086 | 0.81 | MAPT (0.69) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL28865784 | 0.81 | ALDH1A1 (1.00) | ALDH1A1NPC1POLBHSP90AA1RAB9A | |
| SCHEMBL5475341 | 0.81 | MAPT (0.69) | ALDH1A1NPC1POLBHSP90AA1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | disclosed |
| EP-1575919-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | Bayer HealthCare AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004043926-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | BAYER HEALTHCARE AG (DE) | 2004-05-27 | — | — | WO | disclosed |
| EP-0862560-B1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-6235746-B1 | AUTOIMMUNE DISEASES; ANTIPROLIFERATIVE AGENT | CELLTECH THERAPEUTICS, LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-5958935-A | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-09-28 | — | — | US | disclosed |
| EP-0862560-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997019065-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| US-5110831-A | Antiinflammatory agents; leukotriene antagonists | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | ALDH1A1 655/4885NPC1 2323/4885POLB 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.